Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

MCC950

🥰Excellent
Catalog No. T3701Cas No. 210826-40-7
Alias CP-456773

MCC950 (CP-456773) is a NLRP3 inflammasome inhibitor (IC50=7.5-8.1 nM). MCC950 can be used to treat inflammatory diseases, inflammation-related tumors and neurodegenerative diseases.

MCC950

MCC950

🥰Excellent
Purity: 98%
Catalog No. T3701Alias CP-456773Cas No. 210826-40-7
MCC950 (CP-456773) is a NLRP3 inflammasome inhibitor (IC50=7.5-8.1 nM). MCC950 can be used to treat inflammatory diseases, inflammation-related tumors and neurodegenerative diseases.
Pack SizePriceAvailabilityQuantity
2 mg$30In Stock
5 mg$50In Stock
10 mg$79In Stock
25 mg$162In Stock
50 mg$266In Stock
100 mg$415In Stock
1 mL x 10 mM (in DMSO)$55In Stock
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View More

Batch Information

Select Batch
Purity:98%
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
MCC950 (CP-456773) is a NLRP3 inflammasome inhibitor (IC50=7.5-8.1 nM). MCC950 can be used to treat inflammatory diseases, inflammation-related tumors and neurodegenerative diseases.
Targets&IC50
HMDM:8.1 nM, BMDM:7.5 nM
In vitro
METHODS: HEK293 cells and HepG2 cells were treated with MCC950 and cytotoxicity was detected by Resazurin-based fluorescence assay.
RESULTS: MCC950 is non-toxic to HEK293 cells (CC50> 62.5 μM) and HepG2 cells (CC50> 62.5 μM). [1]
METHODS: Human THP-1 cells were treated with MCC950 for 72 hours and the cytotoxicity was detected by the CCK-8 method.
RESULTS: MCC950 inhibited the growth of THP-1 cells (CC50=81.35 μM). [2]
METHODS: Human THP-1 cells were treated with MCC950 for 72 hours and then cytotoxicity was detected by the MTT method.
RESULTS: MCC950 inhibited the growth of THP-1 cells (IC50=98.83 μM). [3]
In vivo
METHODS: To study the anti-inflammatory effect of MCC950, mice were pre-treated with MCC950 for 1 hour and then intraperitoneally injected with LPS.
RESULTS: It was detected 2 hours later that MCC950 could reduce the concentrations of IL-1β and IL-6 in serum, but had little effect on the amount of TNF-α, indicating that MCC950 was active in vivo. [4]
METHODS: To study the anti-inflammatory effect of MCC950, 7-week-old Winnie mice (with Muc2 gene mutation and C57BL/6J background) were used and divided into the MCC950 treatment group and the control group, with 10 mice in each group. The mice in the treatment group were fed fresh feed paste containing 40mg/kg MCC950 every day, while the control group was fed feed paste without MCC950. The experiment lasted for 21 days.
RESULTS: The DAI score of mice in the MCC950 treatment group was significantly reduced, indicating that the consistency of their feces and the blood conditions in the feces were improved. The colonic length of mice in the treatment group increased and the colonic weight decreased, indicating that colonic inflammation was alleviated. The H&E staining RESULTS showed that the colonic inflammation characteristics of mice in the MCC950 treatment group were significantly improved. [5]
METHODS: To study the effect of MCC950 on non-obese diabetes, MCC950 was intraperitoneally injected into 11-week-old female non-obese diabetic (NOD) mice three times a week for three consecutive weeks.
RESULTS: MCC950 treatment led to a significant reduction in salivary secretion and exacerbated the infiltration of white blood cells in the submandibular gland. In addition, it is accompanied by an increase in the number of T cells and B cells, an enhanced Th1 response, and a decrease in the expression of aquaporin 5 in the submandibular gland. [6]
Kinase Assay
Disk diffusion is conducted, except that 10 μg of each antibiotic compound is used per filter. Growth in liquid medium in the presence of CHIR-090 is evaluated as follows: cells from overnight cultures are inoculated into 50 mL portions of LB broth at an A600 of 0.02 and grown with shaking at 30°C. When the A600 reaches 0.15, parallel cultures are treated with either 6 μL of 500 μg/mL CHIR-090 in DMSO or 6 μL of DMSO. To assess cumulative growth, cultures are maintained in log phase growth by 10-fold dilution into pre-warmed medium, containing the same concentrations of DMSO or DMSO/CHIR-090, whenever the A600 reaches 0.4. The minimal inhibitory concentration is defined as the lowest antibiotic concentration at which no measurable bacterial growth is observed in LB medium containing 1% DMSO (v/v), when inoculated at a starting density of A600=0.01. Cultures are incubated with shaking for 24 h at 30°C in the presence of CHIR-090. Experiments are performed in triplicate[1].
Cell Research
MCC950 is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. BMDM are seeded at 5×105/mL or 1×106/mL, HMDM at 5×105/mL and PBMC at 2×106/mL or 5×106/mL in 96 well plates. The following day the overnight medium is replaced and cells are stimulated with 10 ng/mL LPS from Escherichia coli serotype EH100 (ra) TLRgrad for 3 h. Medium is removed and replaced with serum free medium (SFM) containing DMSO (1:1,000), MCC950 (0.001-10 μM), glyburide (200 μM), Parthenolide (10 μM) or Bayer cysteinyl leukotriene receptor antagonist 1-(5-carboxy-2{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid (40 μM) for 30 min. Cells are then stimulated with inflammasome activators: 5 mM adenosine 5'-triphosphate disodium salt hydrate (ATP) (1 h), 1 μg/mL Poly(deoxyadenylic-thymidylic) acid sodium salt (Poly dA:dT) transfected with Lipofectamine 200 (3-4 h), 200 μg/mL MSU (overnight) and 10 μM nigericin (1 h) or S. typhimurium UK-1 strain. Cells are also stimulated with 25 μg/mL Polyadenylic-polyuridylic acid (4 h). For non-canonical inflammasome activation cells are primed with 100 ng/mL Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and 2 μg/mL LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay[1].
SynonymsCP-456773
Chemical Properties
Molecular Weight404.48
FormulaC20H24N2O5S
Cas No.210826-40-7
SmilesCC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12
Relative Density.1.396 g/cm3 (Predicted)
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 83.33 mg/mL (206.02 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4723 mL12.3616 mL24.7231 mL123.6155 mL
5 mM0.4945 mL2.4723 mL4.9446 mL24.7231 mL
10 mM0.2472 mL1.2362 mL2.4723 mL12.3616 mL
20 mM0.1236 mL0.6181 mL1.2362 mL6.1808 mL
50 mM0.0494 mL0.2472 mL0.4945 mL2.4723 mL
100 mM0.0247 mL0.1236 mL0.2472 mL1.2362 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Sci Citations

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy MCC950 | purchase MCC950 | MCC950 cost | order MCC950 | MCC950 chemical structure | MCC950 in vivo | MCC950 in vitro | MCC950 formula | MCC950 molecular weight